Probiotic may be useful adjunctive therapy in pediatric atopic dermatitis
The probiotic Lacticaseibacillus rhamnosus GG (LGG) can potentially be used as adjunctive therapy in pediatric patients with atopic dermatitis (AD), according to a study.
In the ProPAD study, 100 patients between the ages of 6 and 36 months with AD were randomized to receive placebo (Group A) or LGG (1 x 1010 CFU/daily) (Group B) for 12 weeks.
Scoring Atopic Dermatitis (SCORAD) index at baseline (T0) and at 12-week (T12) was used to determine the efficacy of LGG supplementation; a reduction of ≥8.7 was considered as the minimum clinically important difference (MCID). Secondary outcomes were the SCORAD index evaluation at 4-week (T16) after the end of LGG treatment, number of days without rescue medications, changes in Infant Dermatitis Quality Of Life questionnaire (IDQOL), gut microbiome structure and function, and skin microbiome structure.
MCID was achieved in more patients at T12 and T16 in Group B and the number of days without rescue medications was also higher in this group. Patients in group B had a beneficial modulation of gut and skin microbiome.
Reference
Carucci L, Nocerino R, Paparo L, et al. Therapeutic effects elicited by the probiotic Lacticaseibacillus rhamnosus GG in children with atopic dermatitis. The results of the ProPAD trial. Pediatr Allergy Immunol. 2022;33(8):e13836. doi: 10.1111/pai.13836. PMID: 36003050.
